Follow-up in Head and Neck Cancer: Do More Does It Mean Do Better? A Systematic Review and Our Proposal Based on Our Experience

Nerina Denaro, Marco Carlo Merlano, Elvio Grazioso Russi, Nerina Denaro, Marco Carlo Merlano, Elvio Grazioso Russi

Abstract

As the patients population ages, cancer screening increases, and cancer treatments improve, millions more head and neck carcinoma (HNC) patients will be classified as cancer survivors in the future. Change in epidemiology with human papillomavirus related HNC leads to a number of young treated patients. After treatment for HNC intensive surveillance, including ear, nose and throat (ENT) endoscopy, imaging, and serology, confers a survival benefit that became less evident in unresectable recurrence. We performed a comprehensive revision of literature and analyzed the experience of our centre. We revised publications on this topic and added data derived from the interdisciplinary work of experts within medical oncology, ENT, and radiation oncology scientific societies. We retrospectively collected local and distant recurrence of chemoradiation treated patients at Santa Croce and Carle University Hospital. A HNC follow-up program is not already codified and worldwide accepted. There is a need of scheduled follow-up. We suggest adopting a standardized follow-up guideline, although a multidisciplinary approach is frequently requested to tailor surveillance program and treatment on each patient.

Keywords: Head and Neck Neoplasms; Human Papillomavirus; Imaging; Second Primary Tumor; Surveillance.

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1.
Fig. 1.
Follow-up algorithms. For each subsite TSH annually, smoking and alcohol cessation suggested to all patients. Clinical examination according to National Comprehensive Cancer Network should include ear, nose and throat evaluation, pain/xerostomia/depression management, nutritional support, dental care, and speech and swallowing therapy. All CT scan and MRI are considered with contrast. Patients with PS >2, or with comorbidity that contraindicate treatment are not followed up for the disease. TNM, tumor-node-metastasis; CT, computed tomography; MRI, magnetic resonance imaging; PET, positron emission tomography; PS, performance status; TSH, thyroid stimulating hormone; CRT, chemoradiation; M, months; NFE, nasal/pharyngo/laryngeal fiber optic examination; ACF, anterior cranial fossa; MCF, medial cranial fossa; vc, vocal cord. a)If doubt of recurrence or metastatic disease. b)If smoking history >20 pack year. c)T3-4 close margin.

References

    1. Gregoire V, Lefebvre JL, Licitra L, Felip E, EHNS-ESMO-ESTRO Guidelines Working Group Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010 May;21 Suppl 5:v184–6.
    1. Sturgis EM, Miller RH. Second primary malignancies in the head and neck cancer patient. Ann Otol Rhinol Laryngol. 1995 Dec;104(12):946–54.
    1. Roman BR, Goldenberg D, Givi B, Education Committee of American Head and Neck Society (AHNS) AHNS Series-Do you know your guidelines?: guideline recommended follow-up and surveillance of head and neck cancer survivors. Head Neck. 2016 Feb;38(2):168–74.
    1. Digonnet A, Hamoir M, Andry G, Vander Poorten V, Haigentz M, Jr, Langendijk JA, et al. Follow-up strategies in head and neck cancer other than upper aerodigestive tract squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2013 Jul;270(7):1981–9.
    1. Hermans R, Pameijer FA, Mancuso AA, Parsons JT, Mendenhall WM. Laryngeal or hypopharyngeal squamous cell carcinoma: can follow-up CT after definitive radiation therapy be used to detect local failure earlier than clinical examination alone? Radiology. 2000 Mar;214(3):683–7.
    1. Patel SN, Cohen MA, Givi B, Dixon BJ, Gilbert RW, Gullane PJ, et al. Salvage surgery for locally recurrent oropharyngeal cancer. Head Neck. 2016 Apr;38 Suppl 1:E658–64.
    1. Janot F, de Raucourt D, Benhamou E, Ferron C, Dolivet G, Bensadoun RJ, et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol. 2008 Dec;26(34):5518–23.
    1. Kramer NM, Horwitz EM, Cheng J, Ridge JA, Feigenberg SJ, Cohen RB, et al. Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies. Head Neck. 2005 May;27(5):406–14.
    1. Duprez F, Berwouts D, Madani I, Bonte K, Boterberg T, De Gersem W, et al. High-dose reirradiation with intensity-modulated radiotherapy for recurrent head-and-neck cancer: disease control, survival and toxicity. Radiother Oncol. 2014 Jun;111(3):388–92.
    1. Kakria A, Rawat S, Bhutani R, Gupta G, Devnani B, Wahi IK, et al. Retrospective analysis of treatment outcomes following reirradiation in locoregionally recurrent head and neck cancer patients: a single institutional study. Asia Pac J Clin Oncol. 2015 Jun;11(2):129–34.
    1. De Visscher AV, Manni JJ. Routine long-term follow-up in patients treated with curative intent for squamous cell carcinoma of the larynx, pharynx, and oral cavity: does it make sense? Arch Otolaryngol Head Neck Surg. 1994 Sep;120(9):934–9.
    1. Ritoe SC, de Vegt F, Scheike IM, Krabbe PF, Kaanders JH, van den Hoogen FJ, et al. Effect of routine follow-up after treatment for laryngeal cancer on life expectancy and mortality: results of a Markov model analysis. Cancer. 2007 Jan;109(2):239–47.
    1. Lester SE, Wight RG. ‘When will I see you again?’: using local recurrence data to develop a regimen for routine surveillance in post-treatment head and neck cancer patients. Clin Otolaryngol. 2009 Dec;34(6):546–51.
    1. Schwartz DL, Barker J, Jr, Chansky K, Yueh B, Raminfar L, Drago P, et al. Postradiotherapy surveillance practice for head and neck squamous cell carcinoma: too much for too little? Head Neck. 2003 Dec;25(12):990–9.
    1. Boysen M, Lovdal O, Tausjo J, Winther F. The value of follow-up in patients treated for squamous cell carcinoma of the head and neck. Eur J Cancer. 1992;28(2-3):426–30.
    1. Francis DO, Yueh B, Weymuller EA, Jr, Merati AL. Impact of surveillance on survival after laryngeal cancer in the medicare population. Laryngoscope. 2009 Dec;119(12):2337–44.
    1. Flynn CJ, Khaouam N, Gardner S, Higgins K, Enepekides D, Balogh J, et al. The value of periodic follow-up in the detection of recurrences after radical treatment in locally advanced head and neck cancer. Clin Oncol (R Coll Radiol) 2010 Dec;22(10):868–73.
    1. Agrawal A, Hammond TH, Young GS, Avon AL, Ozer E, Schuller DE. Factors affecting long-term survival in patients with recurrent head and neck cancer may help define the role of post-treatment surveillance. Laryngoscope. 2009 Nov;119(11):2135–40.
    1. Cooney TR, Poulsen MG. Is routine follow-up useful after combinedmodality therapy for advanced head and neck cancer? Arch Otolaryngol Head Neck Surg. 1999 Apr;125(4):379–82.
    1. Hsu YB, Chu PY, Liu JC, Lan MC, Chang SY, Tsai TL, et al. Role of chest computed tomography in head and neck cancer. Arch Otolaryngol Head Neck Surg. 2008 Oct;134(10):1050–4.
    1. Wang SJ. Surveillance radiologic imaging after treatment of oropharyngeal cancer: a review. World J Surg Oncol. 2015 Mar;13:94.
    1. Kao J, Vu HL, Genden EM, Mocherla B, Park EE, Packer S, et al. The diagnostic and prognostic utility of positron emission tomography/computed tomography-based follow-up after radiotherapy for head and neck cancer. Cancer. 2009 Oct;115(19):4586–94.
    1. Manikantan K, Dwivedi RC, Sayed SI, Pathak KA, Kazi R. Current concepts of surveillance and its significance in head and neck cancer. Ann R Coll Surg Engl. 2011 Nov;93(8):576–82.
    1. Krabbe CA, Pruim J, Dijkstra PU, Balink H, van der Laan BF, de Visscher JG, et al. 18F-FDG PET as a routine posttreatment surveillance tool in oral and oropharyngeal squamous cell carcinoma: a prospective study. J Nucl Med. 2009 Dec;50(12):1940–7.
    1. Ho AS, Tsao GJ, Chen FW, Shen T, Kaplan MJ, Colevas AD, et al. Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence. Cancer. 2013 Apr;119(7):1349–56.
    1. Dunsky KA, Wehrmann DJ, Osman MM, Thornberry BM, Varvares MA. PET-CT and the detection of the asymptomatic recurrence or second primary lesions in the treated head and neck cancer patient. Laryngoscope. 2013 Sep;123(9):2161–4.
    1. Lee DH, Roh JL, Baek S, Jung JH, Choi SH, Nam SY, et al. Second cancer incidence, risk factor, and specific mortality in head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. 2013 Oct;149(4):579–86.
    1. Jegu J, Binder-Foucard F, Borel C, Velten M. Trends over three de-cades of the risk of second primary cancer among patients with head and neck cancer. Oral Oncol. 2013 Jan;49(1):9–14.
    1. Schwartz LH, Ozsahin M, Zhang GN, Touboul E, De Vataire F, Andolenko P, et al. Synchronous and metachronous head and neck carcinomas. Cancer. 1994 Oct;74(7):1933–8.
    1. Do KA, Johnson MM, Doherty DA, Lee JJ, Wu XF, Dong Q, et al. Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States) Cancer Causes Control. 2003 Mar;14(2):131–8.
    1. Trosman SJ, Koyfman SA, Ward MC, Al-Khudari S, Nwizu T, Greskovich JF, et al. Effect of human papillomavirus on patterns of distant metastatic failure in oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. JAMA Otolaryngol Head Neck Surg. 2015 May;141(5):457–62.
    1. Kwon M, Roh JL, Song J, Lee SW, Kim SB, Choi SH, et al. Effect of metformin on progression of head and neck cancers, occurrence of second primary cancers, and cause-specific survival. Oncologist. 2015 May;20(5):546–53.
    1. Jain KS, Sikora AG, Baxi SS, Morris LG. Synchronous cancers in patients with head and neck cancer: risks in the era of human papillomavirus-associated oropharyngeal cancer. Cancer. 2013 May;119(10):1832–7.
    1. Gleich LL, Ryzenman J, Gluckman JL, Wilson KM, Barrett WL, Redmond KP. Recurrent advanced (T3 or T4) head and neck squamous cell carcinoma: is salvage possible? Arch Otolaryngol Head Neck Surg. 2004 Jan;130(1):35–8.
    1. Wong LY, Wei WI, Lam LK, Yuen AP. Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery. Head Neck. 2003 Nov;25(11):953–9.
    1. Paniello RC, Virgo KS, Johnson MH, Clemente MF, Johnson FE. Practice patterns and clinical guidelines for posttreatment follow-up of head and neck cancers: a comparison of 2 professional societies. Arch Otolaryngol Head Neck Surg. 1999 Mar;125(3):309–13.
    1. National Comprehensive Cancer Network . NCCN guidelines: NCCN guidelines for treatment of cancer by site [Internet] Fort Washington (PA): National Comprehensive Cancer Network; c2015 [cited 2016 May 8]. Available from: .
    1. Hwang HS, Perez DA, Orloff LA. Comparison of positron emission tomography/computed tomography imaging and ultrasound in staging and surveillance of head and neck and thyroid cancer. Laryngoscope. 2009 Oct;119(10):1958–65.
    1. Wierzbicka M, Popko M, Piskadlo K, Czepczynski R, Stankowska A, Pietka T, et al. Comparison of positron emission tomography/computed tomography imaging and ultrasound in surveillance of head and neck cancer: the 3-year experience of the ENT Department in Poznan. Rep Pract Oncol Radiother. 2011 Sep 29;16(5):184–8.
    1. Kangelaris GT, Yom SS, Huang K, Wang SJ. Limited utility of routine surveillance MRI following chemoradiation for advanced-stage oropharynx carcinoma. Int J Otolaryngol. 2010;2010:904297.
    1. Vandecaveye V, De Keyzer F, Nuyts S, Deraedt K, Dirix P, Hamaekers P, et al. Detection of head and neck squamous cell carcinoma with diffusion weighted MRI after (chemo)radiotherapy: correlation between radiologic and histopathologic findings. Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):960–71.
    1. American Head & Neck Society . Education [Internet] Los Angeles (CA): American Head & Neck Society; 2016 [cited 2016 May 8]. Available from:
    1. British Association of Otorhinolaryngology . Head and neck cancer: multidisciplinary management guidelines [Internet] London: British Association of Otorhinolaryngology; 2011 [cited 2016 May 8]. Available from: .
    1. ORL France . Recommandations SFORL [Internet] Paris: ORL France; [cited 2016 May 8]. Available from: .
    1. British Association of Otorhinolaryngology . Medisch Maatschappelijk Werk [Internet] Nederlandse: Werkgroep Hoofd Hals Tumoren; [cited 2016 May 8]. Available from: .
    1. Associazione Italiana di Radioterapia Oncologica (AIRO) Linee guida AIRO [Internet] Roma: Associazione Italiana di Radioterapia Oncologica; [cited 2016 May 8]. Available from: .
    1. Associazione Italiana di Oncologia Medica (AIOM) Linee guida AIOM [Internet] Milano: Associazione Italiana di Oncologia Medica; [cited 2016 May 8]. Available from: .
    1. Kissun D, Magennis P, Lowe D, Brown JS, Vaughan ED, Rogers SN. Timing and presentation of recurrent oral and oropharyngeal squamous cell carcinoma and awareness in the outpatient clinic. Br J Oral Maxillofac Surg. 2006 Oct;44(5):371–6.
    1. Ritoe SC, Bergman H, Krabbe PF, Kaanders JH, van den Hoogen FJ, Verbeek AL, et al. Cancer recurrence after total laryngectomy: treatment options, survival, and complications. Head Neck. 2006 May;28(5):383–8.
    1. Spector JG, Sessions DG, Haughey BH, Chao KS, Simpson J, El Mofty S, et al. Delayed regional metastases, distant metastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx. Laryngoscope. 2001 Jun;111(6):1079–87.
    1. O’Meara WP, Thiringer JK, Johnstone PA. Follow-up of head and neck cancer patients post-radiotherapy. Radiother Oncol. 2003 Mar;66(3):323–6.
    1. Zatterstrom U, Boysen M, Evensen JF. Significance of self-reported symptoms as part of follow-up routines in patients treated for oral squamous cell carcinoma. Anticancer Res. 2014 Nov;34(11):6593–9.
    1. Rennemo E, Zatterstrom U, Boysen M. Impact of second primary tumors on survival in head and neck cancer: an analysis of 2,063 cases. Laryngoscope. 2008 Aug;118(8):1350–6.
    1. Ferreira BC, Marques RV, Khouri L, Santos T, Sa-Couto P, do Carmo Lopes M. Assessment and topographic characterization of locoregional recurrences in head and neck tumours. Radiat Oncol. 2015 Feb;10:41.
    1. Shah K, Te Marvelde L, Collins M, De Abreu Lourenco R, D’Costa I, Coleman A, et al. Safety and cost analysis of an (18)FDG-PET-CT response based follow-up strategy for head and neck cancers treated with primary radiation or chemoradiation. Oral Oncol. 2015 May;51(5):529–35.
    1. Pagh A, Grau C, Overgaard J. A longitudinal study of follow-up activities after curative treatment for head and neck cancer. Acta Oncol. 2015 May;54(5):813–9.
    1. Joshi A, Calman F, O’Connell M, Jeannon JP, Pracy P, Simo R. Current trends in the follow-up of head and neck cancer patients in the UK. Clin Oncol (R Coll Radiol) 2010 Mar;22(2):114–8.
    1. Merlano MC, Monteverde M, Colantonio I, Denaro N, Lo Nigro C, Natoli G, et al. Impact of age on acute toxicity induced by bio- or chemo-radiotherapy in patients with head and neck cancer. Oral Oncol. 2012 Oct;48(10):1051–7.
    1. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010 Jul;363(1):24–35.
    1. O’Sullivan B, Huang SH, Siu LL, Waldron J, Zhao H, Perez-Ordonez B, et al. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol. 2013 Feb;31(5):543–50.
    1. Bledsoe TJ, Noble AR, Hunter GK, Rybicki LA, Hoschar A, Chute DJ, et al. Oropharyngeal squamous cell carcinoma with known human papillomavirus status treated with definitive chemoradiotherapy: patterns of failure and toxicity outcomes. Radiat Oncol. 2013 Jul;8:174.
    1. Subramaniam RM, Alluri KC, Tahari AK, Aygun N, Quon H. PET/CT imaging and human papilloma virus-positive oropharyngeal squamous cell cancer: evolving clinical imaging paradigm. J Nucl Med. 2014 Mar;55(3):431–8.
    1. Tiwana MS, Wu J, Hay J, Wong F, Cheung W, Olson RA. 25 year survival outcomes for squamous cell carcinomas of the head and neck: population-based outcomes from a Canadian province. Oral Oncol. 2014 Jul;50(7):651–6.
    1. Russi EG, Corvo R, Merlotti A, Alterio D, Franco P, Pergolizzi S, et al. Swallowing dysfunction in head and neck cancer patients treated by radiotherapy: review and recommendations of the supportive task group of the Italian Association of Radiation Oncology. Cancer Treat Rev. 2012 Dec;38(8):1033–49.
    1. Bakhshandeh M, Hashemi B, Mahdavi SR, Nikoofar A, Vasheghani M, Kazemnejad A. Normal tissue complication probability modeling of radiation-induced hypothyroidism after head-and-neck radiation therapy. Int J Radiat Oncol Biol Phys. 2013 Feb;85(2):514–21.
    1. Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013 Mar;31(7):845–52.
    1. Ryu CH, Roh JL, Kim SB, Lee SW, Choi SH, Nam SY, et al. Risk factors for non-cancer health events in patients with head and neck squamous cell carcinoma. Ann Oncol. 2013 Apr;24(4):1049–54.
    1. van Agthoven M, van Ineveld BM, de Boer MF, Leemans CR, Knegt PP, Snow GB, et al. The costs of head and neck oncology: primary tumours, recurrent tumours and long-term follow-up. Eur J Cancer. 2001 Nov;37(17):2204–11.
    1. Lang K, Sussman M, Friedman M, Su J, Kan HJ, Mauro D, et al. Incidence and costs of treatment-related complications among patients with advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2009 Jun;135(6):582–8.
    1. Vogelius IR, Bentzen SM, Maraldo MV, Petersen PM, Specht L. Risk factors for radiation-induced hypothyroidism: a literature-based meta-analysis. Cancer. 2011 Dec;117(23):5250–60.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться